Elixir Medical Announces Outstanding Two-Year Results From the EXCELLA BD Randomized Clinical Trial for the CE Mark-Approved DESyne® BD System With Biodegradable Polymer Coating
5/24/2013 10:14:22 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today excellent long-term results of its CE Mark-approved DESyne® BD Novolimus Eluting Coronary Stent System with biodegradable polymer coating compared to the control Endeavor Zotarolimus Eluting Coronary Stent System with durable coating in the EXCELLA BD randomized clinical trial at the 2-year endpoint.
Help employers find you! Check out all the jobs and post your resume.
comments powered by